FDA stinks at policing conflicts

Just when you thought nobody could be worse than the National Institutes of Health at managing financial conflicts of interest among trial investigators... The Inspector General of the Department of Health and Human Services released a linkurl:report;http://www.oig.hhs.gov/oei/reports/oei-05-07-00730.pdf today that indicates a pretty severe lack of oversight over at the Food and Drug Administration. The report found that only one percent of the almost 27,000 clinical investigators contracted by

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Just when you thought nobody could be worse than the National Institutes of Health at managing financial conflicts of interest among trial investigators... The Inspector General of the Department of Health and Human Services released a linkurl:report;http://www.oig.hhs.gov/oei/reports/oei-05-07-00730.pdf today that indicates a pretty severe lack of oversight over at the Food and Drug Administration. The report found that only one percent of the almost 27,000 clinical investigators contracted by the agency in 2007 disclosed a financial interest. In 42% of clinical trials, the FDA never even received the financial disclosure forms from participating investigators that the agency mandates. The FDA not only failed to address these shortcomings, in 20% of the trials where investigators did report a financial conflict, the FDA took no action. In 31% of trials where researchers did submit financial conflict documentation, FDA reviewers didn't even indicate that they read the forms. If this isn't enough to make you smack your forehead and send your morning coffee spraying from one nostril, the FDA also apparently told the inspector general that it wasn't that interested in requiring drug makers to collect and report accurate financial disclosure information from investigators prior to the commencement of clinical trials. "FDA asserted that this additional effort would not be worthwhile because financial interests are only one form of potential bias," the report reads. All of this doesn't appear to be bothering potential clinical trial participants searching to wring a buck out of our foundering economy, though. The __Boston Globe__ linkurl:reported;http://www.boston.com/news/world/europe/articles/2009/01/05/paid_studies_draw_more_interest_in_sour_economy/?page=1 last week that the number of Americans seeking to become paid clinical trial subjects has skyrocketed since the economy went south.
**__Related stories:__***linkurl:Should conflicts mean no NIH grant?;http://www.the-scientist.com/blog/display/55058/
[29th September 2008]*linkurl:Report faults NIH on conflicts;http://www.the-scientist.com/blog/display/54183/
[18th January 2008]*linkurl:CSPI: FDA can manage conflicts better;http://www.the-scientist.com/blog/display/53953/
[3rd December 2007]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
Image of small blue creatures called Nergals. Some have hearts above their heads, which signify friendship. There is one Nergal who is sneezing and losing health, which is denoted by minus one signs floating around it.
June 2025, Issue 1

Nergal Networks: Where Friendship Meets Infection

A citizen science game explores how social choices and networks can influence how an illness moves through a population.

View this Issue
Unraveling Complex Biology with Advanced Multiomics Technology

Unraveling Complex Biology with Five-Dimensional Multiomics

Element Bioscience Logo
Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Twist Bio 
The Scientist Placeholder Image

Seeing and Sorting with Confidence

BD
The Scientist Placeholder Image

Streamlining Microbial Quality Control Testing

MicroQuant™ by ATCC logo

Products

The Scientist Placeholder Image

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

parse-biosciences-logo

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies

waters-logo

How Alderley Analytical are Delivering eXtreme Robustness in Bioanalysis